各种急、慢性肝损伤所导致的终末期肝病严重威胁着人类健康，采取有效措施延缓甚至逆转肝损伤进展已成为目前亟待解决的医学难题。人脐带间充质干细胞(hucMSC)因其体外持续多次传代后仍具有多能性、低免疫原性及不诱导肿瘤发生等特性，被广泛应用于肝损伤疾病治疗的研究。动物实验结果显示，hucMSC注入损伤肝脏后，肝脏氧化应激、炎症反应和肝坏死均明显缓解，肝损伤程度也显著减轻。在肝损伤患者的临床研究中，hucMSC不仅可以减缓炎症反应，还能改善患者免疫状态，延长其术后生存时间。本文综述近年来hucMSC在治疗肝损伤和延缓肝硬化进展中的研究进展。

End-stage liver disease caused by various acute and chronic liver injuries is a serious threat to human health. Taking effective measures to delay or even reverse the progress of liver injury has become a medical problem urgently to be solved. Human umbilical cord mesenchymal stem cell (hucMSC) is widely used in the study of liver injury because of their pluripotency, low immunogenicity, and non-inducing tumorigenesis after continuous passage in vitro. The results of animal experiments showed that after the injection of hucMSC into the injured liver, liver oxidative stress, inflammatory response and liver necrosis were alleviated, and the degree of liver damage was also significantly reduced. In clinical studies of patients with liver injury, hucMSC can not only slow down the inflammatory response, but also improve the immune status of the patients and prolong their postoperative survival. This article reviews the research progress of hucMSC in treating liver injury and delaying the progress of liver cirrhosis in recent years.